Novartis announced that after conducting an interim analysis from the CIRRUS-1 trial of CFZ533 (iscalimab), the company is discontinuing the study in kidney transplant patients.
The U.S. Food and Drug Administration greenlit AstraZeneca’s Farxiga (dapagliflozin) under priority review for the treatment of chronic kidney disease in patients at risk of progression with or without type 2 diabetes.
Alnylam Pharmaceuticals reported positive results for the ILLUMINATE-B Phase III clinical trial evaluating the RNAi therapeutic lumasiran in young children with primary hyperoxaluria type 1 (PH1).
As part of its strategic review and second-quarter 2017 financial reporting, Ardelyx announced the company planned to cut 28 percent of its workforce.
Fremont, Calif.-based Ardelyx announced that its Phase III clinical trial of tenapanor for hyperphosphatemia in patients with end-stage renal disease (ESRD) on dialysis met its primary endpoint.
Atara Biotherapeutics Inc said it would stop developing its kidney drug after the treatment failed to meet the main goal of a mid-stage study. The drug developer said on Monday that the drug, PINTA 745, did not improve physical function, levels of inflammation and blood sugar in patients in the study. Atara’s shares fell nearly […]